

RETRACTION

MicroRNA-155-3p Promotes Breast Cancer Progression Through Down-Regulating CADMI [Retraction]

Zhang G, Zhong L, Luo H, Wang S. Onco Targets Ther. 2019;12:7993-8002.

At the author's request, we, the Editors and Publisher of OncoTargets and Therapy, have retracted the following article.

Following publication of the article, concerns were raised about the duplication of images from Figures 4 and 5 with images from other unrelated articles. Specifically,

- Images from Figure 4I have been duplicated with images from Figure 4C and Figure 5E from Wei W, Zhao X, Zhu J, et al. lncRNA-u50535 promotes the progression of lung cancer by activating CCL20/ERK signaling. *Oncology Reports*. 2019;42:1946-1956. https://doi.org/10.3892/or.2019.7302 and Wang H, Lou C, Ma N. Forskolin exerts anticancer roles in non-Hodgkin's lymphomas via regulating Axin/β-catenin signaling pathway. *Cancer Manag Res*. 2019;11:1685-1696. https://doi.org/10.2147/CMAR.S180754, respectively.
- Images from Figure 5 have been duplicated with images for Figure 6 from Chen W, Wu G, Zhu Y, et al. HOXA10 deteriorates gastric cancer through activating JAK1/STAT3 signaling pathway. *Cancer Manag Res.* 2019;11:6625-6635. https://doi.org/10.2147/CMAR.S201342.

The authors responded to our queries but were unable to provide a satisfactory explanation for the duplicated images or provide satisfactory data for the study. As verifying the validity of published work is core to the integrity of the scholarly record, the authors requested to retract the article and the Editor and Publisher agreed with this decision.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S472068